http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108779100-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-444 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-14 |
| filingDate | 2017-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108779100-B |
| titleOfInvention | 3,4-Dipyridylpyrazole derivatives, their preparation method and their application in medicine |
| abstract | The invention relates to 3,4-dipyridylpyrazole derivatives, a preparation method thereof and their application in medicine. Specifically, the present invention relates to a novel 3,4-dipyridylpyrazole derivative represented by the general formula (I), a preparation method thereof, a pharmaceutical composition containing the derivative, and a therapeutic agent thereof, In particular, use as a TGF-β inhibitor and in the preparation of a medicament for the treatment, prevention or reduction of cancer mediated by TGF-β overexpression, wherein each substituent of the general formula (I) is as defined in the description . |
| priorityDate | 2016-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 191.